{'fraction_non_alphanumeric': 0.03513337670787248, 'fraction_numerical': 0.01951854261548471, 'mean_word_length': 5.329218106995885, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Development and Pharmacokinetics Study of Antifungal Peptide Nanoliposomes by Liquid Chromatography-tandem Mass Spectrometry



 The therapeutic ability and application of antifungal peptide (APs) are limited
by their physico-chemical and biological properties, the nano-liposomal encapsulation would improve
the in vivo circulation and stability.

Objective: To develop a long-circulating liposomal delivery systems encapsulated APs-CGA-N12 with
PEGylated lipids and cholesterol, and investigated through in vivo pharmacokinetics.



 The liposomes were prepared and characterized, a rapid and simple liquid chromatographytandem
mass spectrometry (LC-MS/MS) assay was developed for the determination of antifungal peptide
in vivo, the pharmacokinetic characteristics of APs liposomes were evaluated in rats.



 Liposomes had a large, unilamellar structure, particle size and Zeta potential ranged from 160
to 185 nm and -0.55 to 1.1 mV, respectively. The results indicated that the plasma concentration of
peptides in reference solutions rapidly declined after intravenous administration, whereas the
liposomeencapsulated ones showed slower elimination. The AUC(0-∞) was increased by 3.0-fold in
liposomes in comparison with standard solution (20 mg·kg-1), the half-life (T1/2) was 1.6- and 1.5-fold
higher compared to the reference groups of 20 and 40 mg·kg-1, respectively.



 Therefore, it could be concluded that liposomal encapsulation effectively improved the
bioavailability and pharmacokinetic property of antifungal peptides.